Heparan sulfate binding sites in extracellular matrix (HS binding sites)

Heparan sulfate (HS) binding sites in the extracellular matrix (ECM) serve as essential regulatory platforms for various physiological processes by interacting with a diverse range of ligands, including growth factors, cytokines, and morphogens (Sarrazin et al., 2011, Cold Spring Harb Perspect Biol). These sites are primarily found on heparan sulfate proteoglycans (HSPGs) like perlecan, agrin, and collagen XVIII, where the complex carbohydrate chains sequester signaling molecules to regulate their stability, bioactivity, and spatial distribution (Bishop et al., 2007, Nature). In the context of disease, HS binding sites are frequently exploited by pathogens for cell attachment and entry, and they play a pivotal role in cancer by facilitating angiogenesis and metastasis through the storage and release of pro-tumorigenic factors like VEGF and FGF-2 (Knelson et al., 2014, Nat Rev Cancer). Therapeutic strategies targeting these sites often involve the use of heparin mimetics or small molecules designed to competitively inhibit ligand binding or prevent the enzymatic degradation of HS by heparanase (Ori et al., 2011, Front Biosci). By modulating these interactions, drugs can effectively disrupt pathological signaling cascades and inhibit the progression of inflammatory and neoplastic diseases. Clinical development in this area focuses on balancing the therapeutic inhibition of these sites with the potential for systemic side effects, such as interference with normal coagulation and tissue homeostasis.

Other names

HSPG binding sitesExtracellular matrix heparan sulfateHS-ligand interaction sitesHeparan sulfate proteoglycan binding sites

Competitive inhibition of ligand binding to heparan sulfate chains, displacement of sequestered growth factors from the extracellular matrix, and inhibition of heparanase-mediated degradation of the matrix scaffold.